Brint Family Translational Research Award

The Brint Family Translational Research Award sits under Foundation Fighting Blindness and carries the former TRAP name in the program history. It is aimed at translational work for inherited retinal degeneration and dry age-related macular degeneration, with a clear push toward therapies that can move beyond the lab. The program supports preclinical development across three priority areas: novel medical therapies, genetic technologies, and restorative therapies. It is unusually open for a Foundation Fighting Blindness program, because for-profit companies may apply alongside nonprofits, universities, research organizations, and applicants inside or outside the United States. The program pairs that translational scope with expert mentorship, FDA IND filing support, and clinical trials support. The current cycle uses a letter of intent followed by a full application by invitation, with 2026 dates on the calendar. The best fit is a team that already has a translational package worth advancing and can show a plausible path from experimental work to clinical development.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.